Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis
ClinicalTrials.gov · NCT06715514 · Registry updated: 2026-10-16
- Condition / research focus
- Menopause; Type 2 Diabetes
- Sponsor
- Lia Bally
- Countries with listed sites
- Switzerland
- Registry dates and results
- Start: 2025-02-18. Completion: 2026-12-31 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- GLP-1 Receptor Agonist (drug) — also listed as: Semaglutide
- Menopausal Hormone Therapy (drug) — also listed as: Estradiol, Micronized Progesterone
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Bern, Canton of Bern, Switzerland